Janux Therapeutics suspends ATM equity offering program

Janux Therapeutics, Inc.

Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.
No further sales of common stock under the Sales Agreement until a new prospectus supplement is filed.
Sales Agreement remains in full force and effect; suspension does not terminate it.

item 8.01

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-022266

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.